Plus   Neg

Mylan (MYL) Has Jumped To A 2-Month High After FDA Approval

Mylan (MYL) announced Wednesday morning that it has received approval from the FDA for Glatiramer Acetate Injection 40 mg/mL for 3-times-a-week injection.

Mylan has gapped open sharply higher this morning and is now up 5.46 at $37.99 on above average volume. The stock has jumped to a 2-month high.

by RTTNews Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Follow RTT